Balyasny Asset Management L.P. 13F: New $58M Stake in APGE
Balyasny Asset Management has initiated a new stake in Apogee Therapeutics, acquiring 438,654 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Balyasny Asset Management L.P. opened a new position of 438,654 shares in Apogee Therapeutics, Inc. ($APGE), according to a 13F filing with the SEC dated May 15, 2026. It reported 438,654 shares worth $58.21 million at the end of the quarter.
Since the filing, $APGE is up 0.0% after 1 week, up 6.2% after 1 month and up 63.5% to date (from the $81.14 close on May 15, 2026).
Find the original: Balyasny Asset Management L.P. 13F filings on SEC EDGAR
APGE
Apogee Therapeutics, Inc.
Key Points
- Balyasny Asset Management initiated a new position in Apogee Therapeutics, acquiring 438,654 shares valued at $58.1 million.
- Apogee Therapeutics trades on NasdaqGM with a market cap of $9.99 billion and a 52-week high of $133.00.
- Analysts have mixed views, with recent price targets ranging from $81 to $160 and a consensus rating of strong buy.
Get $APGE trade alerts by text
We text you when insiders, Congress or big funds trade $APGE. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Apogee Therapeutics, Inc. alert may contain errors. Disclosures
Balyasny Asset Management L.P. has taken a new position in Apogee Therapeutics, Inc. (NasdaqGM: APGE), according to its latest Form 13F filing with the SEC. The fund acquired 438,654 shares, valued at approximately $58.1 million, marking a fresh investment as of the reporting period ending on May 15, 2026.
Balyasny Asset Management L.P. vs. the S&P 500
Hypothetical returns from Balyasny Asset Management L.P.'s disclosed trades, not real profit or advice. How we model this.
What Changed in Balyasny Asset Management's Apogee Therapeutics Position
Balyasny Asset Management opened a new position in Apogee Therapeutics by purchasing 438,654 shares. This investment is valued at around $58.1 million, with no prior shares held by the firm, signifying a new entry into Apogee's stock.
Other Institutional Activity in Apogee Therapeutics
Other institutional investors have also been active in Apogee Therapeutics. T. Rowe Price Investment Management, Inc. significantly increased its holdings by 7,568,528 shares, ending with 10,300,984 shares valued at about $867 million, a 277% increase. FMR LLC added 1,037,253 shares, now holding 9,262,291 shares worth approximately $779.6 million, a 12.6% increase. Meanwhile, Wellington Management Group LLP reduced its stake by 370,882 shares, leaving it with 4,375,703 shares valued at $368.3 million, marking a 7.8% decrease.
Apogee Therapeutics Stock Snapshot
Shares of Apogee Therapeutics traded near $132.55 on Tuesday. The company has a market capitalization of $9.99 billion. It is not currently profitable, reflected by its negative forward P/E ratio of -25.52. Apogee's stock has a 52-week low of $34.34 and a high of $133.00. The biotech firm maintains a strong liquidity position with a current ratio of 32.59 and a quick ratio of 32.39.
Recent Earnings
Apogee Therapeutics reported negative earnings per share (EPS) of -4.33, with no net margin or return on equity as the company continues to invest heavily in its pipeline. The next earnings report is expected on August 10, 2026.
Insider Buying and Selling at Apogee Therapeutics, Inc.
Recently, CEO Michael Thomas Henderson sold 20,000 shares at an average price of $83.38 on June 10, 2026, as part of a planned sale. On June 9, 2026, several insiders, including Mark McKenna and William Jones Jr., each bought 7,657 shares, though the transaction price was not disclosed.
Analysts Set New Price Targets
On June 22, 2026, Canaccord Genuity downgraded Apogee to a hold rating with a price target of $135.11. Earlier, on June 8, RBC Capital maintained its hold rating with a $97 target. The consensus among analysts is strong buy, with an average target price of $119.50, based on 16 opinions.
About Apogee Therapeutics
Apogee Therapeutics, Inc., headquartered in Waltham, Massachusetts, is a clinical-stage biotechnology company focusing on developing biologics for inflammatory and immunology-related diseases. Led by CEO Dr. Michael Thomas Henderson, the company is advancing several therapies, including Zumilokibart, which targets conditions like atopic dermatitis and asthma. Founded in 2022, Apogee employs 261 people.
Bottom Line
Balyasny Asset Management's new position in Apogee Therapeutics signals interest in the biotech firm’s potential. Investors watch such moves closely as 13F filings provide a historical snapshot of fund activities. Apogee's stock performance and development progress remain points of interest for analysts and investors alike.
Related Filing Alerts
Source: Balyasny Asset Management L.P.'s 13F filing on $APGE (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Balyasny Asset Management L.P. 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts